Montse Gómez

Hospital Clínic de Barcelona — Spain

Medicine · Health Sciences

18h-index975citations38works6.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myeloproliferative Neoplasms: Diagnosis and Treatment(21), Kruppel-like factors research(12), Acute Myeloid Leukemia Research(10), Chronic Myeloid Leukemia Treatments(8), Eosinophilic Disorders and Syndromes(8)

Publications38 total

Prognostic value of Factor VIII, D-Dimer and High Molecular Risk variants assessing re-thrombosis risk in non-cirrhotic portal vein thrombosis☆
JHEP Reports·2026Open Access
Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR‐T Therapy
eJHaem·2025· 1 citedOpen Access
EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome
Clinical Neurophysiology·2024· 19 citedOpen Access
PB2314: CYTOPENIAS AND BLOOD TRANSFUSION SUPPORT AFTER CAR-T THERAPY
HemaSphere·2023· 2 citedOpen Access
Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer·2022· 29 citedOpen Access
CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review
Current Research in Translational Medicine·2021· 20 citedOpen Access
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study
Blood·2019· 32 citedOpen Access
Second cancers in MPN: Survival analysis from an international study
American Journal of Hematology·2019· 40 citedOpen Access
Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls
Blood·2019· 3 cited
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
Leukemia·2019· 87 citedOpen Access
Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms
Blood·2018· 1 cited
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
Blood Cancer Journal·2018· 37 citedOpen Access
Prognostic risk models for transplant decision-making in myelofibrosis
Annals of Hematology·2018· 9 cited
Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia
British Journal of Haematology·2017· 27 citedOpen Access
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia
PLoS ONE·2017· 6 citedOpen Access
The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method
Blood·2016
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Haematologica·2016· 72 citedOpen Access
JAK2 inhibitors
Medicina Clínica (English Edition)·2016
Inhibidores de JAK2
Medicina Clínica·2016· 9 cited
Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method
Blood·2015· 1 cited
page 1 of 2Next →

Frequent Co-authors

Juan Carlos Hernández‐Boluda(23), Alberto Álvarez‐Larrán(17), Anna Angona(11), Francisca Ferrer‐Marín(10), Manuel Pérez‐Encinas(9), Arturo Pereira(8), Francisco Cervantes(8), María Laura Fox(8), Valentín García‐Gutiérrez(8), María Teresa Gómez‐Casares(7), Ana Kerguelen(7), Eduardo Arellano‐Rodrigo(6), Beatríz Bellosillo(6), Carles Besses(6), Paula Amat(6), Tiziano Barbui(6), Alessandra Carobbio(6), Francesca Palandri(6), Nicola Vianelli(6), Valerio De Stefano(6)